Search Drug Information, Interactions, Images, Dosage & Side Effects

Methylprednisolone + standard care may reduce HBV-ACLF–related mortality 05 Mar 2021

The addition of methylprednisolone to standard care* reduced mortality risk in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF), according to a study from China.

Early DAA treatment cost-effective for kids with HCV

05 Mar 2021

Single-day increase in budesonide–formoterol as needed as good as ICS maintenance in preventing exacerbations in mild asthma

05 Mar 2021

Early RA patients initiating therapy need to stay active, study says

05 Mar 2021

DOAC starter packs being prescribed in adults without acute VTE diagnosis

05 Mar 2021

People with large waist at higher risk of cardiovascular disease

05 Mar 2021

High-flow oxygen offers no benefit in ACS

05 Mar 2021

Tweets more viral than COVID-19

05 Mar 2021

Dabigatran as good as aspirin for recurrent stroke prevention in East Asian patients

05 Mar 2021

Denosumab may reduce need for revision hip arthroplasty due to osteolysis

04 Mar 2021

Novel polygenic risk score predicts prostate cancer risk accurately across ethnicities

04 Mar 2021

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer 14 Jan 2021;
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.